Abstract:
Introduction. Rheumatoid arthritis is a chronic inflammatory disease that is autoimmune in nature. A JAKi may
be utilized to treat RA. It is a member of the DMARDs family. The purpose of this study is to investigate the efficacy
of JAKi in the treatment of RA. Material and methods. A
narrative literature review study was carried out. A bibliographic search was conducted using databases such as
PubMed, WebMed, Google Scholar, National Institutes of
Health, and Med Central. Articles published between 2018
and 2024 were selected using various combinations of keywords such as rheumatoid arthritis, Janus kinase inhibitor, tofacitinib, baricitinib, and Upadacitinib. Results. This
study validates that it is capable of being taken orally due
to its patient friendly nature. Patients who have not responded adequately to biologic DMARDs may use it. Drugs
like tofacitinib, baricitinib, and Upadacitinib that have FDA
approval are widely utilized. A number of people receiving JAKi therapy have side effects that include elevated liver enzymes, cardiovascular risks, hematological abnormalities,
and infections like herpes zoster. For optimal effects in order to lessen the severity of adverse effects, it is utilized as
monotherapy. In the future, the challenge of using JAKi appropriately will arise in clinical settings. Future use of these
medications is anticipated to rise, which means that more
clinical data regarding the long-term outcomes and adverse
effects will need to be gathered for the safe administration
of JAK inhibitors. Conclusions. JAKi are tiny compounds
that specifically target intracellular signaling molecules
that function by preventing the activity of the Janus kinase
enzyme, hence reducing inflammation. In addition to being
widely used as an alternative to biologics, JAKi has become
standard therapy for RA patients who are not responding to
csDMARDS.
